

Resource Summary Report

Generated by [dkNET](#) on Aug 2, 2026

Transglutaminase 2 antibody [CUB 7402]

RRID:AB_2287299

Type: Antibody

Proper Citation

Abcam Cat# ab2386, RRID:AB_2287299

Antibody Information

URL: http://antibodyregistry.org/AB_2287299

Proper Citation: Abcam Cat# ab2386, RRID:AB_2287299

Target Antigen: TGM2

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012:western blot, immunoprecipitation, immunohistochemistry, immunocytochemistry

Antibody Name: Transglutaminase 2 antibody [CUB 7402]

Description: This monoclonal targets TGM2

Target Organism: mouse, dog, human

Clone ID: CUB 7402

Antibody ID: AB_2287299

Vendor: Abcam

Catalog Number: ab2386

Record Creation Time: 20250819T232011+0000

Record Last Update: 20250820T050153+0000

Ratings and Alerts

No rating or validation information has been found for Transglutaminase 2 antibody [CUB 7402].

No alerts have been found for Transglutaminase 2 antibody [CUB 7402].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Caksa S, et al. (2025) Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4+ T Cells. Cancer research.

Ayoubi R, et al. (2024) A guide to selecting high-performing antibodies for Protein-glutamine gamma-glutamyltransferase 2 (TGM2) for use in western blot, immunoprecipitation and immunofluorescence. F1000Research, 13, 481.

Ercolano G, et al. (2022) Gliadin-reactive vitamin D-sensitive proinflammatory ILCPs are enriched in celiac patients. Cell reports, 39(11), 110956.

Beck AC, et al. (2021) AP-2?? Regulates S-Phase and Is a Marker for Sensitivity to PI3K Inhibitor Buparlisib in Colon Cancer. Molecular cancer research : MCR, 19(7), 1156.

Berg TJ, et al. (2021) The Irradiated Brain Microenvironment Supports Glioma Stemness and Survival via Astrocyte-Derived Transglutaminase 2. Cancer research, 81(8), 2101.

Boice M, et al. (2016) Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell, 167(2), 405.